Binds RANKL to prevent osteoclast formation and bone resorption.

Postmenopausal women with osteoporosis at high risk of fracture.

Men with osteoporosis at high risk of fracture.

Glucocorticoid-induced osteoporosis in men and women.

Bone loss in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.

Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.

60 mg via subcutaneous injection every 6 months.

See warnings and precautions.

Pre-existing hypocalcemia

Pregnancy

Known hypersensitivity to Prolia

Do NOT use Xgeva concurrently (same active ingredient).

Hypersensitivity reactions (e.g., anaphylaxis)

Osteonecrosis of the jaw (ONJ): dental evaluation recommended prior.

Atypical femoral fractures: assess for thigh or groin pain.

Multiple vertebral fractures after discontinuation.

Serious infections: including cellulitis, UTIs, and endocarditis.

Dermatologic reactions: eczema, rash, dermatitis.

Musculoskeletal pain: severe cases reported.

Suppression of bone turnover: observed histologically.

Pediatric hypercalcemia: especially in osteogenesis imperfecta cases.